ILYM17064 / RSRB70432 / Paul Barr
Research Question:
What is the safety and efficacy of a new investigational combination of drugs venetoclax
in combination with Ublituximab and Umbralisib (TGR-1202)) that have not been tried
before?
Basic Study Information
Purpose:
Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and
Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03379051?term=venetoclax+in+combination+with+Ublituximab&rank=1
Study Reference #: ILYM17064
Lead Researcher (Principal Investigator)
Lead Researcher:
Paul Barr
Study Contact Information
Study Coordinator: Lauren Mitchell
Email: lauren_mitchell@urmc.rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Lymphoid leukemia, chronic
Trial Not Found
The study you are looking for is not active at this time.
Return to Search